Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Certolizumab pegol in the treatment of Takayasu arteritis: the first experience and prospects

Новиков П. И., Смитиенко И. О., Соколова М. В., Моисеев С. В.
Научно-практическая ревматология
Т. 56, Вып. 3, С. 333-338
Опубликовано: 2018
Тип ресурса: Статья

DOI:10.14412/1995-4484-2018-333-338

Аннотация:
Certolizumab pegol (CZP) is the only pegylated biological agent (BA) that does not contain an Fc fragment, which minimizes its transplacental transfer. Takayasu arteritis mostly occurs in reproductive-aged women. Objective: to evaluate the efficacy and safety of CZP used to treat standard immunosuppressive therapy-resistant Takayasu arteritis. Subjects and methods. The retrospective study enrolled 6 female patients aged 18 to 35 years with Takayasu arteritis who received CZP. The median disease duration before BA usage was 66 months (24 to 204 months). The median duration of immunosuppressive therapy prior to CZP treatment was 92 months (14 to 132 months). All the female patients had taken glucocorticoids and methotrexate before and during CZP therapy. Only four patients had received two to five immunosuppressive drugs at different times prior to BA administration. Three patients had previously used other BAs. The disease activity was determined by the National Institute of Health (NIH
Ключевые слова:
Certolizumab pegol; Takayasu arteritis; TNF-α inhibitors
Язык текста: Русский
ISSN: 1995-4492
Новиков П. И. Павел Игоревич 1982-
Смитиенко И. О.
Соколова М. В.
Моисеев С. В. Сергей Валентинович 1960-
Novikov P. I. Pavel Igorevich 1982-
Smitienko I. O.
Sokolova M. V.
Moiseev S. V. Sergej Valentinovich 1960-
Certolizumab pegol in the treatment of Takayasu arteritis: the first experience and prospects
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 56, Вып. 3 С. 333-338
2018
Статья
Certolizumab pegol Takayasu arteritis TNF-α inhibitors
Certolizumab pegol (CZP) is the only pegylated biological agent (BA) that does not contain an Fc fragment, which minimizes its transplacental transfer. Takayasu arteritis mostly occurs in reproductive-aged women. Objective: to evaluate the efficacy and safety of CZP used to treat standard immunosuppressive therapy-resistant Takayasu arteritis. Subjects and methods. The retrospective study enrolled 6 female patients aged 18 to 35 years with Takayasu arteritis who received CZP. The median disease duration before BA usage was 66 months (24 to 204 months). The median duration of immunosuppressive therapy prior to CZP treatment was 92 months (14 to 132 months). All the female patients had taken glucocorticoids and methotrexate before and during CZP therapy. Only four patients had received two to five immunosuppressive drugs at different times prior to BA administration. Three patients had previously used other BAs. The disease activity was determined by the National Institute of Health (NIH